Company Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Why Investors Should Care
Revenue has grown at a 22.3% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $376.13M (+26.6% YoY); net profit $2.85M.
- Trailing 12 Months Year-on-year growth — revenue -3.2%, earnings -62.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 22.3%, profit CAGR -40.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 22.30% |
| 1 Year: | -3.20% |
Compounded Profit Growth
| 5 Years: | -40.70% |
| 1 Year: | -62.90% |
Stock Price Performance
| 1 Year: | +2.22% |
| 6 Months: | -28.08% |
| 3 Months: | -10.16% |
| 1 Month: | +5.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.16 · Neutral
P/E of 82.14 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 22.3% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 82.1.
- Earnings shrank at -40.7% CAGR over 5 years.
- Trading 45.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PHAR Pharming Group N.V. PHARMA | 11.50 | 82.14 | $813.95M | 0.00% | 5.44% | 3.65% | 22.30% | -40.70% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 93.22M | 97.29M | 106.50M | 72.45M | 90.21M |
| Cost of Revenue | - | - | 8.97M | 7.07M | 21.10M | 6.64M | 14.54M |
| Gross Profit | - | - | 84.25M | 90.22M | 85.40M | 65.80M | 75.67M |
| Operating Expenses | - | - | 75.25M | 74.47M | 83.40M | 71.09M | 75.78M |
| Operating Income | - | - | 9.00M | 15.75M | 2.00M | -5.29M | -111.00K |
| EBITDA | - | - | 9.79M | 23.43M | 9.41M | 1.06M | 8.75M |
| Interest Expense | - | - | 4.00K | 7.95M | 1.40M | 2.69M | 2.68M |
| Pretax Income | - | - | 7.08M | 12.76M | 4.80M | -4.75M | 3.04M |
| Tax Provision | - | - | 2.53M | 5.21M | -500.00K | 459.00K | 1.40M |
| Net Income | - | - | 4.69M | 7.55M | 5.30M | -5.21M | 1.64M |
| Diluted EPS | 0.04 | -0.22 | - | - | 0.07 | -0.07 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 205.62M | 245.32M | 297.20M | 376.13M |
| Cost of Revenue | - | 17.56M | 25.21M | 35.40M | 45.50M |
| Gross Profit | - | 188.06M | 220.10M | 261.80M | 330.63M |
| Operating Expenses | - | 178.20M | 242.39M | 265.47M | 309.75M |
| Operating Income | - | 9.86M | -22.29M | -3.67M | 20.88M |
| EBITDA | - | 33.53M | 9.88M | 16.32M | 34.78M |
| Interest Expense | - | 5.36M | 5.96M | 8.74M | 10.72M |
| Pretax Income | - | 14.99M | -12.01M | -8.49M | 12.85M |
| Tax Provision | - | 1.31M | -1.46M | 3.35M | 10.31M |
| Net Income | - | 13.67M | -10.55M | -11.84M | 2.85M |
| Diluted EPS | - | 0.19 | -0.15 | -0.16 | 0.04 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 425.80M | 462.85M | 399.99M | 499.96M |
| Current Assets | - | 277.50M | 316.34M | 278.44M | 299.47M |
| Cash & Equivalents | - | 207.34M | 61.74M | 54.94M | 145.31M |
| Inventory | - | 42.33M | 56.76M | 55.72M | 64.90M |
| Receivables | - | 20.96M | 35.41M | 41.53M | 41.77M |
| Total Liabilities | - | 221.16M | 244.07M | 178.92M | 222.86M |
| Current Liabilities | - | 59.70M | 77.97M | 73.80M | 115.79M |
| Long Term Debt | - | 131.62M | 136.60M | 78.15M | 92.72M |
| Total Debt | - | 166.69M | 171.54M | 112.31M | 115.78M |
| Total Equity | - | 204.64M | 218.78M | 221.06M | 277.10M |
| Shares Outstanding | - | 656.35M | 671.07M | 680.31M | 701.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 22.46M | -17.30M | -1.79M | 54.71M |
| Investing Cash Flow | - | 5.32M | -129.39M | 31.62M | 26.25M |
| Financing Cash Flow | - | -4.98M | -1.04M | -34.41M | 1.50M |
| Capital Expenditure | - | -1.98M | -1.46M | -796.00K | -755.00K |
| Free Cash Flow | - | 20.48M | -18.77M | -2.59M | 53.95M |
| Net Change in Cash | - | 22.80M | -147.73M | -4.59M | 82.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 91.5% | 89.7% | 88.1% | 87.9% |
| Operating Margin % | - | 4.8% | -9.1% | -1.2% | 5.6% |
| Net Margin % | - | 6.7% | -4.3% | -4.0% | 0.8% |
| ROE % | - | 6.7% | -4.8% | -5.4% | 1.0% |
| ROCE % | - | 2.7% | -5.8% | -1.1% | 5.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Mac Alpha Capital Management, LP | 3.04% | 2.15M | $22.66M |
| 2 | Silverberg Bernstein Capital Management LLC | 0.06% | 41.55K | $438.32K |
| 3 | Crossmark Global Holdings, Inc. | 0.02% | 12.46K | $131.48K |
| 4 | Morgan Stanley | 0.02% | 11.50K | $121.33K |
| 5 | Citadel Advisors Llc | 0.02% | 11.97K | $126.30K |
| 6 | Smartharvest Portfolios, LLC | 0.01% | 10.41K | $109.88K |
| 7 | Knoll Capital Management, LLC | 0.01% | 4.09K | $43.16K |
| 8 | Global Retirement Partners, LLC | - | 456 | $4.81K |
| 9 | Silver Grove Financial Group, Inc. | - | 1.07K | $11.30K |
| 10 | Nalls Sherbakoff Group, Llc | - | 870 | $9.18K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHAR
Pharvaris’ stock jumps on pivotal success in rare genetic disease - Endpoints News
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQdlVncEl4Xy1RZm0yNHd5Ym5OeGpVUE5SNktZNVdqRHphNTVZRGo5RmtodjVoMjAtZ091UmdMU2pZcjdQWnhURERPb3kxYzRwZVItdHZaNEVKdUUyUXM2dXN0eDhhbXFPMGJoeDIxVURxQjNFcE8zS0FIanBtNFljX2c4ejRmRE9CY3BnSX…
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPY0I5MU9YZnhLeFoybE9kbVpIWDh2MGFuS1VUX1RIaFp0MnQ5NUdzaVdKVzFjOUl5WkRpWXNnR3hhakY0dHVZNldSd016cG0zRHhGa29ZSEZ6YVcxcVNLVGgwaC1SWEVwTjM2d3lxS2l1Z18wS1NOSVZWZTNZYWsyeFhFMDNZSGUyWnRaV1…
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPSnpobFlhUnFYSTBNNzZ0c3EweWlmamVMQWtUZTJrLThma3NEeVhsNjB5MGRMUzRSdjFZakotMDE5cFNMUGRURVlIVXBmZVJPaktWcTVqSnRHN1pSQ2lMQm9DYTlwWkVkMjBGbmVCYlREY2JCR3Jzc2J5c2Jwd3JjZ0g3Zi1tMVVDZ1h1bU…
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPUThwdFJnZ0tzTkxpOU9TbE5JaUpCWUtwM0liY3dXUUV6MkdFeVVaU0c3WFJFOFY0SEtQTWpvVWRqSTBIN2lMQUJVRGZQZU44dF9PZW9tMXRjNVVLWk9LVlFDR1YwX1hyRE4xNnlhX1g3UUowN1RPbTk4NjBiY1pmWmgwckdlOUJock82Q2…
(PHAR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPWmlHdVNva3RnWk54Q3B5SVM0VXFVdFBiSkNILWMxdW1lOWZMN1ZHX2xTcWhVd2NSTk1ZX1lGMkpLYXIxZlVUdzRWc0xSazNZeFJ4S3lkMFowSGgyUzY0MlVxUVJsODlNWXE2R204cUw0WG1iSmltdUhYQTg2NDlJNzlXNWszWWxOVlFpZF…
Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNemlNNjJBZlJnTVhXVnI2VGZUWFd3TGF1TzdqWUVHcEFGQ3Jlc3V2NDkyY21WZHpVMWhwMWR2U3BEb2txQm9ST3BVbTNmV3dYTTlPUnZzSlM0Q0J3MXZBbWFVQ3VKM0c1SXpocmJYQUJDVVlOQlFpcFN3UGxFNGRLSmIta3lQbkFyYU1Jam…
PHAR — Frequently Asked Questions
What is the current share price of Pharming Group N.V. (PHAR)?
As of 2026-09-19 21:16 PDT, Pharming Group N.V. (PHAR) trades at $11.50 on NasdaqGM. Its 52-week range is $9.82 to $21.18.
What is the market capitalisation of PHAR?
Pharming Group N.V. (PHAR) has a market capitalisation of $813.95M on NasdaqGM.
What is the P/E ratio of PHAR?
PHAR trades at a trailing price-to-earnings (P/E) ratio of 82.14. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.76.
What is the return on equity (ROE) of PHAR?
PHAR has a return on equity (ROE) of 3.65%. Its return on capital employed (ROCE) is 5.44%.
Is PHAR a good stock to buy?
This page provides a data-driven analysis of Pharming Group N.V. (PHAR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.